Generic Drugs Market
完整報告名稱與涵蓋範圍
Generic Drugs Market Research Report by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration (Oral, Topical, Parenteral, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and by Region (North America, Europe, Aia-Pacific, Rest of the World) Forecast till 2035
報告摘要
Generic Drugs Market Research Report by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration (Oral, Topical, Parenteral, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and by Region (North America, Europe, Aia-Pacific, Rest of the World) Forecast till 2035
Market Analysis
The global generic drugs market is forecast to expand from USD 437.90 billion in 2024 to reach USD 1,148.55 billion by 2035 with a CAGR of 9.36%. Generic drugs are medications that contain the same active ingredients as brand-name drugs and provide the same therapeutic effects, dosage, and safety profile. They are introduced to the market after the original drug’s patent expires, offering a more affordable alternative without compromising quality or efficacy.
In the world generic medicines are becoming a popular choice due to the increased in chronic illnesses like cancer, cardiovascular diseases, neurological disorders, and autoimmune diseases. As the cost of treatment escalates, affordable alternatives become an absolute necessity and generics not only fulfill this requirement but also are therapeutically equivalent to the branded medicines. The growth of the industry is additionally supported by the actions that are taken by the manufacturers of the industry, such as launching new products, using lower-cost formulations, and increasing the production capacity.
However, despite the upsides, the growth of the sector could be restrained by voluntary withdrawal of products from the market owing to problems of quality, packaging, or manufacturing, which result in a loss of trust among patients and unstable supply. Along with this, a doctor's and patient's preference for branded drugs poses a problem to the pace of green penetration.
This changed because of deep R&D investments that go along with the progression of generics in the complex drug categories such as biologics and oncology therapies. The growth of the elderly population in developed as well as developing countries is a constant factor that leads to a sustained demand for their long-term treatment for multiple diseases. The governments are giving priority to the generics through their cost-containment strategies, substitution policies, and reimbursement incentives. The generic drugs market with these set targeted growth has combined drivers and opportunities overshadowing restraints, will still be at the center of ensuring global access to affordable healthcare.
Market Segmentation Insights
The global market is classified based on the route of administration, comprising oral, topical, parenteral, and others.
Depending on the indication, the global drugs market is segmented into central nervous system (CNS), cardiovascular, urology, oncology, respiratory, and others.
Based on the distribution channel, the global generic drug market is divided into hospital, retail, and online pharmacy.
Regional Perspectives
North America continues to dominate the global generic drugs market, supported by a strong presence of established pharmaceutical companies and favorable regulatory pathways for generic approvals. The United States, in particular, benefits from a well-working healthcare system and robust demand for cost-effective alternatives to branded drugs. Government policies such as the Hatch-Waxman Act and initiatives to encourage generic substitution have further accelerated market growth. Canada also plays a role, with its expanding portfolio of generics catering to both domestic needs and export demands.
Europe holds a significant share of the market, with countries like Germany, the UK, and France leading in generic drug adoption. Stringent price control mechanisms and reimbursement policies across the region drive the preference for generics over branded products. The European Medicines Agency’s streamlined approval process aids in faster market entry for new generic formulations. Eastern European nations are witnessing rising consumption, thanks to increasing healthcare access and cost-sensitive patient populations.
The Asia-Pacific region is emerging as a high-growth market for generic drugs, fueled by large populations and the growing burden of chronic diseases. India remains a global powerhouse for generic manufacturing, exporting extensively to the US, Europe, and other regions. China’s focus on healthcare reforms and the promotion of low-cost medicines is also propelling the sector. Other markets such as Japan and Australia are seeing increased uptake due to aging populations and government-led cost-containment efforts.
In the Rest of the World segment, Latin America, the Middle East, and Africa are experiencing steady growth in generic drug adoption. Brazil and Mexico are notable Latin American markets, benefiting from government procurement programs and local manufacturing capacity. The Middle East is investing in domestic production to reduce dependence on imports, while African countries are gradually improving their regulatory frameworks. Rising healthcare infrastructure and growing awareness of generics are expected to support long-term market expansion.
Major Competitors
Key competitors in the global generic drugs market are Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Sun Pharmaceuticals Industries, Fresenius Kabi, Lupin Pharmaceuticals, Inc., Endo International plc, Aurobindo Pharma, Aspen Holdings, Cipla Ltd., and Fresenius SE & Co. KGaA.
授權報價
| Single User Price | $4,950 USD |
| Multi User Licence (up to 10 users) | $5,950 USD |
| Enterprisewide Price (Global Site License) | $7,250 USD |
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ...... 17
2 MARKET INTRODUCTION ... 19
2.1 DEFINITION ........ 19
2.2 SCOPE OF THE STUDY ........... 19
2.3 RESEARCH OBJECTIVE .......... 19
2.4 MARKET STRUCTURE ........... 19
3 RESEARCH METHODOLOGY .................. 20
3.1 OVERVIEW ......... 20
3.2 DATA FLOW ....... 22
3.2.1 DATA MINING PROCESS ... 22
3.3 PURCHASED DATABASE: ...... 23
3.4 SECONDARY SOURCES: ........ 24
3.4.1 SECONDARY RESEARCH DATA FLOW: .... 25
3.5 PRIMARY RESEARCH: ........... 26
3.5.1 PRIMARY RESEARCH DATA FLOW: ........ 27
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED .......... 28
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE .............. 28
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ...... 29
3.6.1 REVENUE ANALYSIS APPROACH ............ 29
3.7 DATA FORECASTING............. 30
3.7.1 DATA FORECASTING TYPE ..................... 30
3.8 DATA MODELING .................. 31
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ... 31
3.8.2 DATA MODELING: ............. 32
3.9 TEAMS AND ANALYST CONTRIBUTION ..................... 34
4 MARKET DYNAMICS ........... 36
4.1 INTRODUCTION ..................... 36
4.2 DRIVERS .............. 36
4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE ................. 36
4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS ..................... 37
4.2.3 RISING DEMAND FOR AFFORDABLE MEDICATIONS ...... 38
4.3 RESTRAINTS ....... 39
4.3.1 VOLUNTARY PRODUCT RECALLS FROM MARKET PLAYERS ............... 39
4.3.2 BRAND LOYALTY AND DOCTOR PREFERENCES ............ 40
4.4 OPPORTUNITY .. 41
4.4.1 INVESMTENT ON RESEARCH & DEVELOPMENT (R&D) FOR GENERIC MEDICINE ....... 41
4.4.2 RISING AGING POPULATION .................. 41
5 MARKET FACTOR ANALYSIS .................. 42
5.1 PORTER'S FIVE FORCES MODEL .............. 42
5.1.1 THREAT OF NEW ENTRANTS .................. 42
5.1.2 BARGAINING POWER OF SUPPLIERS ...... 43
5.1.3 THREAT OF SUBSTITUTES ..................... 43
5.1.4 BARGAINING POWER OF BUYERS ........... 43
5.1.5 INTENSITY OF RIVALRY .... 43
5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET .............. 44
6 GLOBAL GENERIC DRUGS MARKET, BY INDICATION .................... 46
6.1 OVERVIEW ......... 46
6.2 CENTRAL NERVOUS SYSTEM (CNS) ........ 48
6.3 CARDIOVASCULAR ............... 49
6.4 UROLOGY ........... 49
6.5 ONCOLOGY ........ 49
6.6 RESPIRATORY .... 50
6.7 OTHERS ............... 50
7 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION ............ 51
7.1 OVERVIEW ......... 51
7.2 ORAL .................... 53
7.3 TOPICAL.............. 54
7.4 PARENTERAL ..... 54
7.5 OTHERS ............... 54
8 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL .................. 55
8.1 OVERVIEW ......... 55
8.2 HOSPITAL PHARMACY ......... 57
8.3 RETAIL PHARMACY .............. 57
8.4 ONLINE PHARMACY ............. 58
9 GLOBAL GENERIC DRUGS MARKET, BY REGION ..... 59
9.1 OVERVIEW ......... 59
9.2 NORTH AMERICA .................. 60
9.2.1 US............... 63
9.2.2 CANADA ..... 64
9.3 EUROPE ............... 65
9.3.1 GERMANY ... 68
9.3.2 FRANCE ...... 69
9.3.3 UK .............. 70
9.3.4 ITALY .......... 71
9.3.5 SPAIN ......... 72
9.3.6 REST OF EUROPE .............. 73
9.4 ASIA-PACIFIC ..... 75
9.4.1 CHINA ......... 78
9.4.2 INDIA .......... 79
9.4.3 JAPAN ........ 80
9.4.4 SOUTH KOREA .................. 81
9.4.5 AUSTRALIA . 82
9.4.6 REST OF ASIA-PACIFIC ..... 84
9.5 REST OF THE WORLD ........... 86
9.5.1 MIDDLE EAST ................... 88
9.5.2 AFRICA ....... 90
9.5.3 SOUTH AMERICA .............. 91
10 COMPETITIVE LANDSCAPE .................... 94
10.1 INTRODUCTION ..................... 94
10.2 MARKET SHARE ANALYSIS, 2024 ............. 94
10.3 COMPETITOR DASHBOARD ..................... 95
10.4 PUBLIC PLAYERS STOCK SUMMARY ...... 96
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL ................ 96
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ....... 97
10.6.1 PRODUCT LAUNCH ........... 97
10.6.2 PRODUCT LAUNCH / PRODUCT APPROVAL ................. 97
10.6.3 EXPANSION ..................... 99
11 COMPANY PROFILES ......... 100
11.1 SUN PHARMACEUTICAL INDUSTRIES LTD. ............... 100
11.1.1 COMPANY OVERVIEW ....... 100
11.1.2 FINANCIAL OVERVIEW ...... 101
11.1.3 PRODUCTS OFFERED ........ 102
11.1.4 KEY DEVELOPMENTS ........ 103
11.1.5 SWOT ANALYSIS .............. 103
11.1.6 KEY STRATEGIES .............. 104
11.2 LUPIN PHARMACEUTICALS, INC. ............ 105
11.2.1 COMPANY OVERVIEW ....... 105
11.2.2 FINANCIAL OVERVIEW ...... 106
11.2.3 PRODUCTS OFFERED ........ 107
11.2.4 KEY DEVELOPMENTS ........ 108
11.2.5 SWOT ANALYSIS .............. 109
11.2.6 KEY STRATEGIES .............. 109
11.3 ENDO INTERNATIONAL PLC .................... 110
11.3.1 COMPANY OVERVIEW ....... 110
11.3.2 FINANCIAL OVERVIEW ...... 111
11.3.3 PRODUCTS OFFERED ........ 111
11.3.4 KEY DEVELOPMENTS ........ 112
11.3.5 KEY STRATEGIES .............. 112
11.4 AUROBINDO PHARMA ......... 113
11.4.1 COMPANY OVERVIEW ....... 113
11.4.2 FINANCIAL OVERVIEW ...... 114
11.4.3 PRODUCTS OFFERED ........ 115
11.4.4 KEY DEVELOPMENTS ........ 116
11.4.5 KEY STRATEGIES .............. 116
11.5 ASPEN HOLDINGS .................. 117
11.5.1 COMPANY OVERVIEW ....... 117
11.5.2 FINANCIAL OVERVIEW ...... 118
11.5.3 PRODUCTS OFFERED ........ 119
11.5.4 KEY DEVELOPMENTS ........ 119
11.5.5 KEY STRATEGIES .............. 119
11.6 CIPLA LTD .......... 120
11.6.1 COMPANY OVERVIEW ....... 120
11.6.2 FINANCIAL OVERVIEW ...... 121
11.6.3 PRODUCTS OFFERED ........ 121
11.6.4 KEY DEVELOPMENTS ........ 123
11.6.5 SWOT ANALYSIS .............. 124
11.6.6 KEY STRATEGIES .............. 124
11.7 NOVARTIS AG .... 125
11.7.1 COMPANY OVERVIEW ....... 125
11.7.2 FINANCIAL OVERVIEW ...... 126
11.7.3 PRODUCTS OFFERED ........ 126
11.7.4 KEY DEVELOPMENTS ........ 127
11.7.5 SWOT ANALYSIS .............. 128
11.7.6 KEY STRATEGIES .............. 128
11.8 TEVA PHARMACEUTICAL INDUSTRIES LTD .............. 129
11.8.1 COMPANY OVERVIEW ....... 129
11.8.2 FINANCIAL OVERVIEW ...... 130
11.8.3 PRODUCTS OFFERED ........ 130
11.8.4 KEY DEVELOPMENTS ........ 131
11.8.5 SWOT ANALYSIS .............. 132
11.8.6 KEY STRATEGIES .............. 132
11.9 FRESENIUS SE & CO. KGAA .. 133
11.9.1 COMPANY OVERVIEW ....... 133
11.9.2 FINANCIAL OVERVIEW ...... 134
11.9.3 PRODUCTS OFFERED ........ 134
11.9.4 KEY DEVELOPMENTS ........ 137
11.9.5 KEY STRATEGIES .............. 137
11.10 VIATRIS INC. ...... 138
11.10.1 COMPANY OVERVIEW ....... 138
11.10.2 FINANCIAL OVERVIEW ...... 139
11.10.3 PRODUCTS OFFERED ........ 139
11.10.4 KEY DEVELOPMENTS ........ 140
11.10.5 KEY STRATEGIES .............. 141
12 DATA CITATIONS ................ 142
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 32
TABLE 2 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 47
TABLE 3 GLOBAL GENERIC DRUGS MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2019–2035 (USD BILLION) 48
TABLE 4 GLOBAL GENERIC DRUGS MARKET, FOR CARDIOVASCULAR, BY REGION, 2019–2035 (USD BILLION) 49
TABLE 5 GLOBAL GENERIC DRUGS MARKET, FOR UROLOGY, BY REGION, 2019–2035 (USD BILLION) 49
TABLE 6 GLOBAL GENERIC DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019–2035 (USD BILLION) 49
TABLE 7 GLOBAL GENERIC DRUGS MARKET, FOR RESPIRATORY, BY REGION, 2019–2035 (USD BILLION) 50
TABLE 8 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION) 50
TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 52
TABLE 10 GLOBAL GENERIC DRUGS MARKET, FOR ORAL, BY REGION, 2019–2035 (USD BILLION) 53
TABLE 11 GLOBAL GENERIC DRUGS MARKET, FOR TOPICAL, BY REGION, 2019–2035 (USD BILLION) 54
TABLE 12 GLOBAL GENERIC DRUGS MARKET, FOR PARENTERAL, BY REGION, 2019–2035 (USD BILLION) 54
TABLE 13 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION) 54
TABLE 14 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 56
TABLE 15 GLOBAL GENERIC DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019–2035 (USD BILLION) 57
TABLE 16 GLOBAL GENERIC DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019–2035 (USD BILLION) 57
TABLE 17 GLOBAL GENERIC DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019–2035 (USD BILLION) 58
TABLE 18 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019–2035 (USD BILLION) 59
TABLE 19 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION) 61
TABLE 20 NORTH AMERICA GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 62
TABLE 21 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 62
TABLE 22 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 62
TABLE 23 US GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 63
TABLE 24 US GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 63
TABLE 25 US GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 63
TABLE 26 CANADA GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 64
TABLE 27 CANADA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 64
TABLE 28 CANADA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 64
TABLE 29 EUROPE: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION) 66
TABLE 30 EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 66
TABLE 31 EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 67
TABLE 32 EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 67
TABLE 33 GERMANY: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 68
TABLE 34 GERMANY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 68
TABLE 35 GERMANY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 68
TABLE 36 FRANCE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 69
TABLE 37 FRANCE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 69
TABLE 38 FRANCE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 70
TABLE 39 UK: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 70
TABLE 40 UK: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 70
TABLE 41 UK: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 71
TABLE 42 ITALY: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 71
TABLE 43 ITALY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 71
TABLE 44 ITALY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 72
TABLE 45 SPAIN: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 72
TABLE 46 SPAIN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 73
TABLE 47 SPAIN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 73
TABLE 48 REST OF EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 73
TABLE 49 REST OF EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 74
TABLE 50 REST OF EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 74
TABLE 51 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION) 76
TABLE 52 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 76
TABLE 53 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 77
TABLE 54 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 77
TABLE 55 CHINA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 78
TABLE 56 CHINA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 78
TABLE 57 CHINA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 78
TABLE 58 INDIA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 79
TABLE 59 INDIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 79
TABLE 60 INDIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 80
TABLE 61 JAPAN: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 80
TABLE 62 JAPAN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 80
TABLE 63 JAPAN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 81
TABLE 64 SOUTH KOREA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 81
TABLE 65 SOUTH KOREA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 82
TABLE 66 SOUTH KOREA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 82
TABLE 67 AUSTRALIA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 82
TABLE 68 AUSTRALIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 83
TABLE 69 AUSTRALIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 83
TABLE 70 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 84
TABLE 71 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 84
TABLE 72 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 85
TABLE 73 REST OF THE WORLD: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION) 87
TABLE 74 REST OF THE WORLD: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 87
TABLE 75 REST OF THE WORLD: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 88
TABLE 76 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 88
TABLE 77 MIDDLE EAST: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 88
TABLE 78 MIDDLE EAST: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 89
TABLE 79 MIDDLE EAST: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 89
TABLE 80 AFRICA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 90
TABLE 81 AFRICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 90
TABLE 82 AFRICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 90
TABLE 83 SOUTH AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION) 91
TABLE 84 SOUTH AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION) 91
TABLE 85 SOUTH AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION) 92
TABLE 86 PUBLIC PLAYERS STOCK SUMMARY
TABLE 87 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 88 PRODUCT LAUNCH
TABLE 89 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 90 EXPANSION
TABLE 91 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED
TABLE 92 SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 93 LUPIN PHARMACEUTICALS, INC.: PRODUCT OFFERED
TABLE 94 LUPIN PHARMACEUTICALS, INC.: KEY DEVELOPMENTS
TABLE 95 ENDO INTERNATIONAL PLC: PRODUCT OFFERED
TABLE 96 ENDO INTERNATIONAL PLC: KEY DEVELOPMENTS
TABLE 97 AUROBINDO PHARMA: PRODUCT OFFERED
TABLE 98 AUROBINDO PHARMA: KEY DEVELOPMENTS
TABLE 99 ASPEN HOLDINGS: PRODUCT OFFERED
TABLE 100 CIPLA LTD.: PRODUCTS OFFERED
TABLE 101 CIPLA LTD.: KEY DEVELOPMENTS
TABLE 102 NOVARTIS AG: PRODUCTS OFFERED
TABLE 103 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 104 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED
TABLE 105 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
TABLE 106 FRESENIUS SE & CO. KGAA: PRODUCT OFFERED
TABLE 107 FRESENIUS SE & CO. KGAA: KEY DEVELOPMENTS
TABLE 108 VIATRIS INC.: PRODUCT OFFERED
TABLE 109 VIATRIS INC.: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 GLOBAL GENERIC DRUGS MARKET: STRUCTURE 19
FIGURE 2 GLOBAL GENERIC DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035) 36
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 39
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 40
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GENERIC DRUGS MARKET 42
FIGURE 6 GLOBAL GENERIC DRUGS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION) 46
FIGURE 7 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2024 & 2035 (USD BILLION) 47
FIGURE 8 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY INDICATION, 2024 48
FIGURE 9 GLOBAL GENERIC DRUGS MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION) 51
FIGURE 10 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 & 2035 (USD BILLION) 52
FIGURE 11 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2024 53
FIGURE 12 GLOBAL GENERIC DRUGS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION) 55
FIGURE 13 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD BILLION) 56
FIGURE 14 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024 56
FIGURE 15 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019 & 2035 (USD BILLION) 59
FIGURE 16 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY REGION, 2024 60
FIGURE 17 NORTH AMERICA MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2035 (USD BILLION) 60
FIGURE 18 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2024 & 2035 (USD BILLION) 61
FIGURE 19 NORTH AMERICA: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY, 2024 61
FIGURE 20 EUROPE: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION) 65
FIGURE 21 EUROPE: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 66
FIGURE 22 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION) 75
FIGURE 23 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 76
FIGURE 24 REST OF THE WORLD: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION) 86
FIGURE 25 REST OF THE WORLD: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%) 87
FIGURE 26 GENERIC DRUGS MARKET PLAYERS: COMPETITIVE ANALSIS, 2024 94
FIGURE 27 COMPETITOR DASHBOARD: GLOBAL GENERIC DRUGS MARKET 95
FIGURE 28 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT 101
FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 103
FIGURE 30 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT 106
FIGURE 31 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS 109
FIGURE 32 ENDO INTERNATIONAL PLC: FINANCIAL OVERVIEW SNAPSHOT 111
FIGURE 33 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT 114
FIGURE 34 ASPEN HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT 118
FIGURE 35 CIPLA LTD.: FINANCIAL OVERVIEW 121
FIGURE 36 CIPLA LTD.: SWOT ANALYSIS 124
FIGURE 37 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 126
FIGURE 38 NOVARTIS AG: SWOT ANALYSIS 128
FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 130
FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 132
FIGURE 41 FRESENIUS SE & CO. KGAA: FINANCIAL OVERVIEW SNAPSHOT 134
FIGURE 42 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT
139
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們